ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States. It operates through Research and Development Activities for the Development of Innovative Drugs; and Contract Research Organization (CRO) Activities segments. The company develops CER-001, a recombinant HDL mimetic biopharmaceutical in a Phase III trial for the treatment of lecithin cholesterol acyltransferase (LCAT) deficiency, as well as in a Phase II trial for the treatment of sepsis. It is also developing ABNX-100, a strategic extension into ophthalmology of CER-001 that is in preclinical trial for the treatment of uveitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was incorporated in 2005 and is headquartered in Balma, France.
Frequently asked questions
What sector does Abionyx Pharma SA (ABNX) operate in?
Abionyx Pharma SA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Abionyx Pharma SA (ABNX) current stock price?
As of the latest data, Abionyx Pharma SA stock price is €1.96, with a previous close of €1.96.
What is Abionyx Pharma SA (ABNX) current market capitalization?
Abionyx Pharma SA market cap is approximately 82.73 million.
What is Abionyx Pharma SA (ABNX) Earnings Per Share (EPS)?
The trailing EPS is -€0.16, and the forward EPS is -€0.30.
Does Abionyx Pharma SA (ABNX) pay dividends?
No. Abionyx Pharma SA does not pay a dividend.
What is Abionyx Pharma SA (ABNX) beta (volatility) score?
Abionyx Pharma SA has a beta of 0.453, indicating lower volatility than the overall market.
